Q1 EPS Estimate for CRISPR Therapeutics Lifted by Analyst

Key Points

• Zacks Research has revised its earnings estimates for CRISPR Therapeutics, projecting a loss of ($1.38) per share for Q1 2026, slightly better than the previous estimate of ($1.40).
• CRISPR Therapeutics' stock has recently seen varied analyst ratings, with nine analysts giving a "Buy" rating and a consensus price target of $71.60, while the stock is currently trading at $51.83.
• Insider purchasing activity has been significant, with Director Simeon George acquiring nearly 1 million shares at an average cost of $52.03, representing a 133.69% increase in his ownership.

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Research analysts at Zacks Research raised their Q1 2026 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a report issued on Wednesday, August 27th. Zacks Research analyst Team now expects that the company will earn ($1.38) per share for the quarter, up from their previous forecast of ($1.40). Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Zacks Research also issued estimates for CRISPR Therapeutics' Q2 2026 earnings at ($1.28) EPS, Q3 2026 earnings at ($1.33) EPS, Q4 2026 earnings at ($1.30) EPS, FY2026 earnings at ($5.28) EPS, Q1 2027 earnings at ($1.27) EPS, Q2 2027 earnings at ($1.16) EPS and FY2027 earnings at ($4.61) EPS.

Several other brokerages also recently issued reports on CRSP. Piper Sandler reissued an "overweight" rating and issued a $105.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, June 27th. JMP Securities reaffirmed a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Barclays lifted their price objective on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. HC Wainwright lifted their price objective on shares of CRISPR Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a report on Thursday, August 7th. Finally, Wall Street Zen upgraded shares of CRISPR Therapeutics to a "sell" rating in a research note on Friday, May 16th. Nine equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $71.60.

CRISPR Therapeutics Stock Performance

Shares of CRSP traded up $2.12 during midday trading on Monday, hitting $54.86. 2,731,024 shares of the company traded hands, compared to its average volume of 2,175,021. CRISPR Therapeutics has a 52 week low of $30.04 and a 52 week high of $71.13. The firm has a 50 day moving average of $56.36 and a 200-day moving average of $45.52. The stock has a market cap of $4.99 billion, a price-to-earnings ratio of -10.10 and a beta of 1.81.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.47) by $0.18. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.The business had revenue of $0.89 million during the quarter, compared to analyst estimates of $6.44 million. During the same quarter in the prior year, the business posted ($1.49) EPS. CRISPR Therapeutics's revenue for the quarter was up 72.5% compared to the same quarter last year.

Insider Transactions at CRISPR Therapeutics

In other news, Director Simeon George purchased 989,812 shares of the company's stock in a transaction dated Wednesday, July 16th. The stock was acquired at an average price of $52.03 per share, with a total value of $51,499,918.36. Following the purchase, the director directly owned 1,730,179 shares in the company, valued at approximately $90,021,213.37. This represents a 133.69% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 4.30% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP lifted its stake in shares of CRISPR Therapeutics by 14.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 947,301 shares of the company's stock valued at $37,283,000 after purchasing an additional 122,695 shares during the period. Tower Research Capital LLC TRC grew its stake in CRISPR Therapeutics by 499.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,453 shares of the company's stock worth $215,000 after buying an additional 4,544 shares during the period. Stifel Financial Corp grew its stake in CRISPR Therapeutics by 7.2% during the fourth quarter. Stifel Financial Corp now owns 43,128 shares of the company's stock worth $1,698,000 after buying an additional 2,891 shares during the period. Hsbc Holdings PLC lifted its position in shares of CRISPR Therapeutics by 16.1% during the fourth quarter. Hsbc Holdings PLC now owns 17,496 shares of the company's stock worth $685,000 after purchasing an additional 2,426 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of CRISPR Therapeutics by 3.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 24,563 shares of the company's stock worth $967,000 after purchasing an additional 800 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.